{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["128(1)"],"submitter":["Behar Harpaz S"],"pubmed_abstract":["<h4>Background</h4>A national, lung cancer screening programme is under consideration in Australia, and we assessed cost-effectiveness using updated data and assumptions.<h4>Methods</h4>We estimated the cost-effectiveness of lung screening by applying screening parameters and outcomes from either the National Lung Screening Trial (NLST) or the NEderlands-Leuvens Longkanker Screenings ONderzoek (NELSON) to Australian data on lung cancer risk, mortality, health-system costs, and smoking trends using a deterministic, multi-cohort model. Incremental cost-effectiveness ratios (ICERs) were calculated for a lifetime horizon.<h4>Results</h4>The ICER for lung screening compared to usual care in the NELSON-based scenario was AU$39,250 (95% CI $18,150-108,300) per quality-adjusted life year (QALY); l"],"journal":["British journal of cancer"],"pagination":["91-101"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9814515"],"repository":["biostudies-literature"],"pubmed_title":["Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes."],"pmcid":["PMC9814515"],"pubmed_authors":["Weber MF","Canfell K","Wade S","Behar Harpaz S","Zalcberg JR","Fong K","Marshall H","Tammemagi MC","Caruana M","Cressman S","Vaneckova P","McWilliams A","Ngo PJ","Sarich PEA"],"additional_accession":[]},"is_claimable":false,"name":"Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes.","description":"<h4>Background</h4>A national, lung cancer screening programme is under consideration in Australia, and we assessed cost-effectiveness using updated data and assumptions.<h4>Methods</h4>We estimated the cost-effectiveness of lung screening by applying screening parameters and outcomes from either the National Lung Screening Trial (NLST) or the NEderlands-Leuvens Longkanker Screenings ONderzoek (NELSON) to Australian data on lung cancer risk, mortality, health-system costs, and smoking trends using a deterministic, multi-cohort model. Incremental cost-effectiveness ratios (ICERs) were calculated for a lifetime horizon.<h4>Results</h4>The ICER for lung screening compared to usual care in the NELSON-based scenario was AU$39,250 (95% CI $18,150-108,300) per quality-adjusted life year (QALY); l","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T12:37:45.183Z","creation":"2025-04-04T12:37:45.183Z"},"accession":"S-EPMC9814515","cross_references":{"pubmed":["36323879"],"doi":["10.1038/s41416-022-02026-8"]}}